NovoCure's Phase 3 TRIDENT trial fails to show survival benefit for early TTFields therapy

Filed June 18, 2026 · Period ending June 18, 2026 · ~1 min read

Key Changes

• high

  Phase 3 TRIDENT trial missed primary endpoint: early-start TTFields showed no survival advantage over delayed start (17.7 vs 17.5 months median survival, p=0.519). This negative result blocks a potential label expansion for earlier treatment initiation.

  Item 7.01 — Regulation FD Disclosure verify on EDGAR →
• medium

  TTFields therapy remained safe when started during chemoradiation, with no new safety signals and device-related safety consistent with prior glioblastoma studies. Safety profile supports continued use in current approved indication.

  Item 7.01 — Regulation FD Disclosure verify on EDGAR →
• low

  Full trial results accepted for presentation at ASTRO 2026 Annual Meeting, which may provide additional scientific detail beyond top-line data.

  Item 7.01 — Regulation FD Disclosure verify on EDGAR →